Expert: New Guidance May Demand Clinical Decision Support Software Re-Evaluation
Businesses should reevaluate the classification of their clinical decision software based on a new FDA guidance, Kyle Faget of Foley & Lardner LLP tells Medtech Insight.
You may also be interested in...
Don’t Worry, You (Probably) Won’t Have To Deal With ONC: Algorithm Transparency Rule May Have Surprise Effects On Medtech Firms
Epstein Becker Green attorney Alaap Shah breaks down the HHS ONC’s 800-page rule on algorithm transparency and information blocking.
A warning letter from the US FDA to device manufacturer Abiomed highlights industry’s criticism that the agency’s final guidance on clinical decision support software is flawed and oversteps regulatory boundaries.
A citizen petition filed by a University of Florida Law Professor posits that the FDA’s CDS Guidance violates the first amendment.